Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
167.86
Dollar change
+2.84
Percentage change
1.72
%
Index- P/E- EPS (ttm)-8.50 Insider Own0.91% Shs Outstand95.36M Perf Week4.74%
Market Cap16.02B Forward P/E- EPS next Y-2.70 Insider Trans-0.05% Shs Float94.60M Perf Month11.96%
Income-881.71M PEG- EPS next Q-2.47 Inst Own46.51% Short Float1.85% Perf Quarter-10.21%
Sales2.46B P/S6.52 EPS this Y4.94% Inst Trans-0.43% Short Ratio5.82 Perf Half Y-19.12%
Book/sh33.82 P/B4.96 EPS next Y66.33% ROA-14.47% Short Interest1.75M Perf Year-30.15%
Cash/sh33.37 P/C5.03 EPS next 5Y- ROE-22.26% 52W Range132.95 - 272.49 Perf YTD-6.93%
Dividend Est.- P/FCF- EPS past 5Y5.63% ROI-23.47% 52W High-38.40% Beta0.62
Dividend TTM- Quick Ratio2.09 Sales past 5Y92.60% Gross Margin81.13% 52W Low26.26% ATR (14)7.40
Dividend Ex-Date- Current Ratio2.32 EPS Y/Y TTM56.56% Oper. Margin-49.12% RSI (14)56.92 Volatility5.69% 4.16%
Employees10000 Debt/Eq0.26 Sales Y/Y TTM73.65% Profit Margin-35.86% Recom1.21 Target Price270.67
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q17.71% Payout- Rel Volume0.61 Prev Close165.02
Sales Surprise-0.41% EPS Surprise-0.20% Sales Q/Q66.91% EarningsFeb 26 BMO Avg Volume300.24K Price167.86
SMA209.61% SMA502.88% SMA200-10.20% Trades Volume183,199 Change1.72%
Date Action Analyst Rating Change Price Target Change
Feb-06-24Resumed JP Morgan Overweight $185
Sep-12-23Initiated Macquarie Outperform $259
Aug-17-23Initiated Jefferies Buy $287
Jul-17-23Initiated Citigroup Buy $275
Jun-30-23Downgrade Bernstein Outperform → Mkt Perform $335 → $196
Jan-12-23Initiated Daiwa Securities Buy $308
Oct-13-22Upgrade SVB Leerink Mkt Perform → Outperform $177 → $200
Oct-13-22Upgrade Guggenheim Neutral → Buy $205
Aug-09-22Resumed JP Morgan Overweight $296
Mar-17-22Downgrade SVB Leerink Outperform → Mkt Perform $300 → $177
Feb-29-24 10:00AM
Feb-28-24 08:05AM
Feb-27-24 06:00AM
12:05AM
Feb-26-24 06:32AM
06:00AM Loading…
06:00AM
05:00AM
Feb-20-24 10:49AM
Feb-13-24 12:58PM
Feb-07-24 06:47AM
Feb-02-24 05:04AM
Jan-31-24 06:47AM
Jan-23-24 06:00AM
Jan-04-24 09:26PM
Dec-27-23 08:06PM
06:00AM Loading…
Dec-22-23 06:00AM
Dec-21-23 06:01AM
Dec-19-23 11:41AM
Nov-30-23 09:55AM
Nov-29-23 04:01PM
Nov-28-23 06:00AM
Nov-22-23 06:04AM
Nov-21-23 07:14AM
06:59AM
06:14AM
06:00AM
Nov-17-23 06:00AM
Nov-15-23 05:05AM
Nov-14-23 05:07PM
09:55AM
07:00AM Loading…
Nov-10-23 07:00AM
12:22AM
Nov-09-23 04:01PM
Nov-08-23 06:00AM
Oct-20-23 06:00AM
Oct-17-23 04:01PM
04:01PM
Oct-16-23 06:00AM
Oct-13-23 11:51AM
Oct-05-23 05:17PM
Sep-19-23 06:22AM
06:15AM
06:10AM
06:00AM
Sep-12-23 09:53AM
Aug-31-23 07:00AM
Aug-17-23 09:39AM
Aug-02-23 06:00AM
Jul-21-23 07:50AM
Jul-14-23 09:58AM
Jul-13-23 08:12AM
Jul-12-23 07:00AM
Jul-10-23 07:00AM
Jul-07-23 07:00AM
Jun-15-23 01:20PM
08:37AM
03:00AM
Jun-09-23 03:01AM
May-30-23 07:00AM
07:00AM
May-25-23 05:05PM
02:45PM
May-24-23 07:00AM
May-17-23 07:00AM
May-11-23 07:02AM
May-09-23 09:29AM
May-06-23 08:00AM
May-05-23 06:01AM
May-04-23 07:00AM
Apr-28-23 01:39PM
Apr-26-23 10:27AM
Apr-25-23 08:45AM
07:00AM
Apr-20-23 01:50PM
07:00AM
Apr-19-23 07:22PM
Apr-17-23 02:32PM
02:32PM
02:30PM
02:30PM
08:41AM
Apr-14-23 02:45PM
Apr-13-23 12:02PM
10:45AM
07:00AM
Apr-10-23 03:07AM
Apr-06-23 05:24PM
Mar-30-23 07:00AM
Mar-27-23 06:25AM
Mar-25-23 02:53PM
Mar-21-23 07:00AM
Mar-17-23 12:26PM
Mar-16-23 12:06PM
Mar-13-23 05:30AM
05:30AM
Mar-08-23 12:36PM
Feb-28-23 11:54AM
09:35AM
Feb-27-23 09:35AM
07:00AM
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wang Julia AijunChief Financial OfficerFeb 29Sale167.0839766,3310Mar 04 05:22 PM
Lee Chan HenrySVP, General CounselJul 31Sale216.26791171,0590Aug 02 05:10 PM
Wang Julia AijunChief Financial OfficerJul 03Sale179.5547284,7470Jul 06 05:02 PM
Wu XiaobinPresident, COO & GM ChinaJun 26Sale182.371,495272,6360Jun 27 05:20 PM
Wang LaiGlobal Head of R&DJun 26Sale181.921,108201,5670Jun 27 05:24 PM
Wang Julia AijunChief Financial OfficerJun 23Sale182.85840153,5940Jun 27 05:22 PM
Sanders Corazon (Corsee) D.DirectorJun 23Sale182.32578105,3810Jun 27 05:21 PM
Wang LaiGlobal Head of R&DJun 20Sale192.421,325254,9550Jun 20 06:53 PM
HHLR ADVISORS, LTD.10% OwnerJun 14Sale207.72273,72856,857,986142,888,241Jun 15 07:25 PM
HHLR ADVISORS, LTD.10% OwnerJun 13Sale183.31924,400169,448,353143,161,969Jun 15 07:25 PM
HHLR ADVISORS, LTD.10% OwnerJun 12Sale195.211,250,212244,057,178144,086,369Jun 12 09:57 PM
HHLR ADVISORS, LTD.10% OwnerJun 09Sale182.89542,65299,244,890145,336,581Jun 12 09:57 PM
HHLR ADVISORS, LTD.10% OwnerJun 08Sale218.141,163,825253,881,790145,879,233Jun 12 09:57 PM
Wu XiaobinPresident, COO & GM ChinaJun 07Sale224.733,291739,5990Jun 09 05:44 PM
Wang LaiGlobal Head of R&DJun 07Sale224.74462103,8280Jun 09 05:46 PM
Wu XiaobinPresident, COO & GM ChinaMay 08Sale253.727,0001,776,0370May 10 04:44 PM
Wang XiaodongChair, Scientific Advisory BrdMar 08Option Exercise0.1367,6358,79367,635Mar 10 06:48 PM
Wang XiaodongChair, Scientific Advisory BrdMar 08Sale226.0367,63515,287,3390Mar 10 06:48 PM